On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Shandong Shengdi Pharmaceutical had received an NMPA Clinical Trial Approval Notice for HRS-1597 tablets, approving clinical trials for the weight management indication. The drug is a Class 1 innovative drug independently developed by the company with no similar drug yet approved in China or overseas, and cumulative R&D investment in the project of approximately RMB 16.9 million.
On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Guangdong Hengrui Pharmaceutical had received an NMPA Clinical Trial Approval Notice for SHR-1179 injection, approving clinical trials for the weight management indication. The drug is a therapeutic Class 1 biological product independently developed by the company, with no drug targeting the same pathway yet approved in China or overseas, and cumulative R&D investment in the project of approximately RMB 24.2 million.
On 7 September 2026, CHINA OVERSEAS (00688.HK) announced that China Asset Management and CITIC Securities had submitted application materials for the registration and listing of a public commercial REIT with the CSRC and the SZSE. The company proposes to spin off the Foshan Qiandeng Lake Unicenter shopping mall project into a public REIT for independent listing on the SZSE, with expected gross proceeds of approximately RMB 1.534 billion and a group subscription for approximately 20% of the issued fund units, after which the project company will be 100% held by the REIT and deconsolidated. As all applicable percentage ratios are below 5%, the proposed spin-off is not subject to the Chapter 14 reporting, announcement or shareholders' approval requirements, and the company has applied for a waiver from the assured entitlement requirement under paragraph 3(f) of Practice Note 15.
On 7 September 2026, CIFI HOLD GP (00884.HK) announced its unaudited operational data for August 2026, recording contracted sales (including contracted sales of joint ventures and associates) of approximately RMB 660 million with contracted sales area of approximately 62,400 sq.m. and an average contracted selling price of approximately RMB 11,700 per sq.m. in the month, and cumulative contracted sales of approximately RMB 6.30 billion with contracted sales area of approximately 649,800 sq.m. and shareholders' attributable contracted sales of approximately RMB 3.33 billion for January to August 2026.
On 7 September 2026, AGILE GROUP (03383.HK) announced its unaudited operational data for August 2026, recording aggregate pre-sales of approximately RMB 380 million with a corresponding floor area of approximately 46,000 sq.m. at an average price of RMB 8,234 per sq.m. in the month, and cumulative pre-sales of approximately RMB 4.67 billion with a floor area of approximately 520,000 sq.m. at an average price of RMB 8,977 per sq.m. for the eight months ended 31 August 2026.
On 7 September 2026, CIL GROUP (01719.HK) announced that its wholly-owned subsidiary had entered into a limited partnership agreement with Changjiang Venture Capital, Hubei Ganghang and Wuhan Ganghang to establish a port and shipping development fund with total capital commitments of RMB 300 million (approximately HKD 351 million), to which the subsidiary will contribute RMB 8 million, representing about 2.66%. As the counterparties are associates of controlling shareholder Hubei Port Group, the transaction constitutes a connected transaction; with the highest applicable percentage ratio exceeding 0.1% but below 5%, it is subject to reporting and announcement requirements but exempt from circular and independent shareholders' approval.
On 7 September 2026, SHOUGANG LANZA (02553.HK) voluntarily announced that its H shares had been included in the eligible securities list of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect (collectively, Stock Connect), effective from the same day, enabling eligible mainland investors to buy and sell its H shares directly through the scheme, which is expected to broaden the company's investor base and may increase the trading liquidity of its H shares.
On 7 September 2026, UNISOUND (09678.HK) voluntarily announced progress in its medical intelligence business, having recently won multiple benchmark smart healthcare projects, including large-model projects at leading Class 3A hospitals, an intelligent fund supervision project for a leading insurance institution and a regional medical intelligence construction project, with a combined contract value of nearly RMB 100 million. The projects are based on vertical large models trained on the company's proprietary foundational model U2, covering in-hospital diagnosis and treatment, fund supervision and regional data governance.
On 7 September, Hong Kong's three major indices came under pressure: the Hang Seng Index fell 0.93% to close at 25,413.12 points and the Hang Seng TECH Index fell 0.92%, with turnover of HK$ 209.673 billion. The Stock Connect eligible list was formally adjusted today, with 54 securities added and 15 removed; Baidu was formally included in Stock Connect, and Citi expects about HK$ 47 billion of incremental inflows over the next 2 to 4 months. On the trading front, optical communication, PCB and other computing-power hardware chains led gains, with CIG up over 24% and ZJ INNOLIGHT up nearly 20%; Chinese banking H-shares broadly corrected and AI application and heavyweight technology stocks weakened. Southbound capital recorded net buying of HK$ 1.275 billion.
On 7 September 2026, The Stock Exchange of Hong Kong Limited announced that the listing status of WISDOM WEALTH (00007.HK) would be cancelled with effect from 9:00 a.m. on 9 September 2026 under Rule 6.01A(1) of the Listing Rules. The company's shares have been suspended since 2 April 2024, and it failed to resume trading on or before 1 October 2025, leading to two delisting decisions by the Listing Committee and an upholding review decision by the Listing Review Committee on 27 August 2026.
September 7, 2026—the three major Hong Kong indices collectively retreated, with the Hang Seng Index down 0.93%, the Hang Seng TECH Index down 0.92%, and the Hang Seng China Enterprises Index down 1.46%. The Hang Seng Index's total market turnover was HK$209.7 billion, Southbound funds saw a net inflow of HK$1.275 billion.
On 7 September 2026, YUK WING GP (01536.HK) announced that Ms. Hu Lanying had resigned as executive director and chief executive officer to focus on other business development with effect from the same day, and that Miss Tsang Ka Yan (formerly known as Tsang Ka Yan) had been appointed as executive director, also with effect from 7 September 2026. Miss Tsang has entered into a one-year service agreement and is entitled to an annual director's fee of HKD 1,000,000, holding office until the first annual general meeting following her appointment.
Weekly Hong Kong ETF Scale Change Statistics (First Week of September 2026)
On 7 September 2026, INNOGEN-B (02591.HK) voluntarily announced that WANG QINGHUA, Ph.D., the group's founder, chairman and a substantial shareholder, together with executive directors Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing, had each voluntarily undertaken not to dispose of any shares or interests in the company for six months commencing from 15 August 2026, when the controlling shareholder's lock-up period under the global offering expired.
On 7 September 2026, BANK OF CHINA (03988.HK) announced the completion of its 2026 second-tranche TLAC non-capital bonds (Bond Connect), with a total size of RMB 40 billion: Tranche 1 of RMB 20 billion is a 4-year fixed-rate bond with a coupon of 1.69% (with a conditional issuer redemption option at the end of the third year), and Tranche 2 of RMB 20 billion is a 6-year fixed-rate bond with a coupon of 1.79% (with a conditional issuer redemption option at the end of the fifth year). Net proceeds will be used to enhance the bank's total loss-absorbing capacity.
On 7 September 2026, POWERLONG (01238.HK) announced unaudited operational data for August 2026, with contracted sales (together with contracted sales of jointly controlled entities and associates) of approximately RMB 460 million and contracted sales area of approximately 55,007 sq.m. in the month, and cumulative contracted sales of approximately RMB 4,430 million with cumulative contracted sales area of approximately 441,356 sq.m. for the eight months ended 31 August 2026.
